Haematology and Leukemia
The sponsor’s clinical research activity is centred on chronic lymphocytic leukemia, with attention to treatment options used in the first-line setting for newly diagnosed patients. Its work is closely aligned with clinical decision-making in blood cancers, particularly where long-term disease control and tolerability are important.
- Chronic lymphocytic leukemia
- Blood cancer treatment
- First-line oncology care
The research setting includes multiple collaborating sites within Poland, reflecting involvement in specialist care for patients with haematological malignancies.
Targeted Therapy in Oncology
Clinical interest extends to modern targeted approaches for chronic lymphocytic leukemia, including therapies directed at disease pathways relevant to lymphoid malignancies. The sponsor is engaged in evaluating treatment combinations used in routine oncology practice.
- Targeted cancer therapy
- Lymphoid malignancy management
- Combination treatment in leukemia
Its research profile is focused on therapeutic options that may improve disease control while maintaining acceptable tolerability in patients with CLL.
Immunotherapy and Antibody-based Treatment
The sponsor’s trial portfolio includes interest in antibody-based treatment strategies, particularly regimens involving obinutuzumab within the care of chronic lymphocytic leukemia. This places emphasis on immune-directed treatment concepts in haematology.
- Monoclonal antibody therapy
- Immune-directed treatment
- Obinutuzumab-based regimens
The research activity supports clinical evaluation of antibody-containing combinations for patients requiring systemic treatment for leukemia.
Hospital-based Clinical Research
As a non-commercial hospital sponsor in Walbrzych, the organisation contributes to specialist clinical research within a healthcare setting that supports patient access to investigational treatment pathways. Its activity is concentrated in one active trial with ongoing recruitment.
- Specialist hospital research
- Multicentre clinical collaboration
- Patient recruitment in oncology studies
The sponsor’s research footprint is concentrated in a single disease area, with collaboration across several research sites supporting clinical investigation in haematologic oncology.
